ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more
ValiRx plc (VAL) - Total Liabilities
Latest total liabilities as of June 2025: £87.45K GBP
Based on the latest financial reports, ValiRx plc (VAL) has total liabilities worth £87.45K GBP as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ValiRx plc - Total Liabilities Trend (2001–2024)
This chart illustrates how ValiRx plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ValiRx plc Competitors by Total Liabilities
The table below lists competitors of ValiRx plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BitFuFu Inc. Warrant
NASDAQ:FUFUW
|
USA | $282.19 Million |
|
Widad Group Bhd
KLSE:0162
|
Malaysia | RM546.10 Million |
|
Heliogen Inc
OTCQX:HLGN
|
USA | $9.65 Million |
|
Major Development Public Company Limited
BK:MJD
|
Thailand | ฿13.93 Billion |
|
TON Strategy Co
NASDAQ:TONX
|
USA | $22.42 Million |
|
SYNOPSYS (SYP.SG)
STU:SYP
|
Germany | €3.90 Billion |
|
NuCana PLC
NASDAQ:NCNA
|
USA | $6.39 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down ValiRx plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ValiRx plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ValiRx plc (2001–2024)
The table below shows the annual total liabilities of ValiRx plc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | £346.41K | +52.93% |
| 2023-12-31 | £226.51K | +51.37% |
| 2022-12-31 | £149.65K | +36.59% |
| 2021-12-31 | £109.56K | -39.94% |
| 2020-12-31 | £182.40K | -86.80% |
| 2019-12-31 | £1.38 Million | +14.77% |
| 2018-12-31 | £1.20 Million | -32.54% |
| 2017-12-31 | £1.78 Million | -31.17% |
| 2016-12-31 | £2.59 Million | +340.51% |
| 2015-12-31 | £588.55K | -29.52% |
| 2014-12-31 | £835.08K | -4.68% |
| 2013-12-31 | £876.10K | +234.86% |
| 2012-12-31 | £261.63K | +85.56% |
| 2011-12-31 | £141.00K | -71.97% |
| 2010-12-31 | £503.00K | -33.64% |
| 2009-12-31 | £758.00K | +85.33% |
| 2008-12-31 | £409.00K | +321.65% |
| 2007-12-31 | £97.00K | -7.62% |
| 2006-12-31 | £105.00K | +1066.67% |
| 2006-03-31 | £9.00K | -95.61% |
| 2005-12-31 | £205.00K | +127.78% |
| 2004-12-31 | £90.00K | +52.54% |
| 2003-12-31 | £59.00K | -82.80% |
| 2002-12-31 | £343.00K | -43.68% |
| 2001-12-31 | £609.00K | -- |